Insmed (INSM) to Release Earnings on Thursday

Insmed (NASDAQ:INSM) will post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Insmed to post earnings of ($1.21) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The company had revenue of $83.70 million during the quarter, compared to analysts’ expectations of $82.15 million. The business’s revenue was up 41.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.20) earnings per share. On average, analysts expect Insmed to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Insmed Stock Performance

Shares of INSM stock opened at $25.59 on Thursday. The stock has a fifty day moving average price of $26.84 and a 200 day moving average price of $27.05. The stock has a market cap of $3.80 billion, a PE ratio of -4.79 and a beta of 0.92. Insmed has a 1 year low of $18.08 and a 1 year high of $32.00.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Wells Fargo & Company reaffirmed an “overweight” rating and set a $55.00 price objective on shares of Insmed in a report on Monday, April 1st. UBS Group assumed coverage on Insmed in a report on Tuesday, February 27th. They set a “buy” rating and a $46.00 price objective for the company. Truist Financial assumed coverage on Insmed in a report on Tuesday, April 23rd. They set a “buy” rating and a $48.00 price objective for the company. StockNews.com raised Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Guggenheim raised their price target on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.92.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.